May 16, 2012
Takeda Pharmaceutical announced on May 11 that in the PIII GEMINI II trial in Crohn’s disease patients, the investigational antibody drug vedolizumab (development code: MLN002) achieved remission in the induction and maintenance phases, the primary endpoint of the trial. The...read more